Cadrenal Therapeutics CEO Quang Pham Sells Shares
Quang Pham sold 513 shares of Cadrenal Therapeutics, raising $1,621.
Key Points
- Quang Pham, CEO of Cadrenal Therapeutics, sold 513 shares on June 17, 2026, for $1,621.08.
- Cadrenal Therapeutics, Inc., a Nasdaq-listed biotech firm, develops therapies for immune and thrombotic conditions.
- The company has a market cap of $9.5 million and a 52-week high of $14.64, with no dividend payout.
Important disclosure: EarningsIQ is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD), sold 513 shares of the company on June 17, 2026. The shares were sold at an average price of $3.16, amounting to a total transaction value of $1,621.08. The sale was part of a planned transaction under Rule 10b5-1.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. is a biotechnology company based in Ponte Vedra, Florida. It focuses on developing innovative therapies for serious immune and thrombotic conditions. The company is working on Tecarfarin, an oral medication in Phase 3 trials aimed at preventing heart attacks and strokes in patients needing long-term anticoagulation. Cadrenal is also developing CAD-1005 and Frunexian, targeting heparin-induced thrombocytopenia and acute hospital settings, respectively. Founded in 2022, Cadrenal collaborates with Abbott Global Enterprises Limited to enhance Tecarfarin's efficacy and safety.
Cadrenal Therapeutics, Inc. Stock Up 12.9%
Shares of Cadrenal Therapeutics are trading near $3.50. The company has a market capitalization of approximately $9.5 million. Although the company is not currently profitable, it has a forward P/E ratio of -0.79. The stock's beta is 1.613, indicating higher volatility than the market. Over the past year, the stock has ranged from a low of $3.02 to a high of $14.64. Its 50-day moving average is $5.02, and the 200-day moving average is $8.50. Cadrenal maintains a current ratio of 2.68 and a quick ratio of 2.17, reflecting its liquidity position.
$CVKD stock price
Daily closing prices, year to date. Not investment advice.
Bottom Line
Quang Pham's recent sale of Cadrenal Therapeutics shares is part of a planned transaction, highlighting the structured approach executives often take in managing their holdings. Investors keep an eye on insider sales for insights into management's views on the company's prospects. As a late-stage biopharmaceutical firm, Cadrenal Therapeutics' ongoing clinical trials and collaborations remain crucial for its future growth. The company's financial metrics, such as its market cap and stock volatility, offer additional context for stakeholders.
Get Cadrenal Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CVKD, sent to your inbox. Free, and you can unsubscribe anytime.
Related Filing Alerts
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.
S